Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NJNitin JainNPNaveen PemmarajuPBPrithviraj Bose

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows 67% overall response rate in patients with Richter transformation, suggesting effective combination therapy.

Key Points

  • This research aims to evaluate the efficacy of pirtobrutinib, venetoclax, and obinutuzumab in treating Richter transformation.
  • Enrolled patients with Richter transformation from chronic lymphocytic leukemia.
  • Administered pirtobrutinib, venetoclax, and obinutuzumab in a combined therapy approach.
  • Evaluated treatment response by Lugano criteria using imaging and bone marrow assessments.
  • Achieved a 67% overall response rate among treated patients.
  • Seven out of twelve patients reached complete metabolic response after treatment.
  • 12-month event-free survival and overall survival rates were 73% and 82%, respectively.

Cite This Study

Jain et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cff7https://doi.org/10.1182/blood-2025-89
View Full Paper
Ask AI
Bookmark
Share